- Hematopoietic Stem Cell Transplantation
- Recombinant Human Interferon-gamma Treatment
- Prophylactic Immunoglobulin Therapy
- Antimicrobial Therapy
- Prophylactic Therapy
- Fucose Supplementation
- Monoclonal Antibodies
- Coagulation Factors
Leukocyte Adhesion Deficiency Management Market size was valued at USD 6,223.8 million in 2023 and is poised to grow at an 6.8% CAGR from 2024 to 2030. Leukocyte Adhesion Deficiency (LAD) is a rare autosomal recessive disorder characterized by immunodeficiency resulting in recurrent infections. The advent of genome sequencing and increased interest in genome studies have played an important role in enhancing and understanding the overall genetics of leukocyte adhesion deficiency. Contemporary research has generated new frontiers for understanding the pathogenesis of common variable primary immunodeficiency. Recently, the adoption of DNA sequencing, RNA sequencing, epigenetic, and proteomic profiles is growing, to assess common variable primary immunodeficiency including leukocytic adhesion deficiency. Scientists and researchers are increasingly focusing on understanding the genetics of primary immunodeficiency which will help in expanding the market. Moreover, the increasing prevalence of spinal cord injuries and primary immunodeficiency is rising, furthering the demand for novel treatments.
Credited to several discoveries in monogenic forms of common variable primary immunodeficiency, significant progress in sequencing technologies is triggered. In the past decade, owing to advancements in technology and research, participants of the primary immunodeficiency market are swaying toward the use of omics-based technologies and integrating next-generation platforms in the leukocyte adhesion deficiency therapeutics which will also help in market expansion in the forecast period. Moreover, as the leukocyte adhesion deficiency management market continues to evolve, it provides various opportunities for stakeholders to collaborate, innovate, and invest in research and development initiatives to further advance treatment modalities and address unmet medical needs in the field of leukocyte adhesion deficiency management. However, the growth of the leukocyte adhesion deficiency therapeutics market is expected to be restrained due to the high cost of immunotherapy and the side effects of immunodeficiency disease treatments like leukocyte adhesion deficiency treatment. Moreover, stem cell transplantation therapies have a very high success rate. In addition, stem cell reconstitution is a first-line treatment for severe leukocyte adhesion deficiency type I. These benefits provided by this therapy will augment this segment’s growth during the forecast period.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The increasing prevalence of spinal cord injuries is expected to drive the growth of the leukocyte adhesion deficiency management market. Spinal cord injury, resulting from damage to any part of the spinal cord or associated nerves, often leads to complications such as autonomic dysfunction, including conditions such as hyperhidrosis. This issue is linked to heightened sympathetic activity in the spinal cord segment located just below the injury site. As indicated by the National Spinal Cord Injury Statistical Center (NSCISC) in March 2022, the estimated annual incidence of traumatic spinal cord injury (SCI) in the United States stands at approximately 54 cases per one million people, equating to about 18,000 new SCI cases annually. Managing leukocyte adhesion deficiency can significantly benefit those with primary immunodeficiency, potentially enhancing the understanding of immune system disorders and fostering the development of improved diagnostic techniques and therapies for these conditions. For example, statistics gathered during World Primary Immunodeficiency (WPI) Awareness Week 2023 by the Peace Hospital indicated that an estimated 60 lakh individuals worldwide are affected by PI, with 70% to 90% of cases remaining undiagnosed. Hence, the rising prevalence of primary immunodeficiency is set to propel the growth of the leukocyte adhesion deficiency management market.
Leukocyte Adhesion Deficiency Management Market was valued at USD 6,223.8 million in 2023 and is expected to grow at an 6.8% CAGR from 2024 to 2030.
Hematopoietic Stem Cell Transplantation is expected to dominate the leukocyte adhesion deficiency management market with maximum share.
Asia Pacific is estimated to grow at the highest CAGR over the forecast period.
North America accounts for the largest market share and is expected to be the primary market driver in the leukocyte adhesion deficiency management market.
The high cost of immunotherapy and the side effects of immunodeficiency disease treatments are expected to limit the growth of the leukocyte adhesion deficiency management market.
1.Executive Summary |
2.Global Leukocyte Adhesion Deficiency Management Market Introduction |
2.1.Global Leukocyte Adhesion Deficiency Management Market - Taxonomy |
2.2.Global Leukocyte Adhesion Deficiency Management Market - Definitions |
2.2.1.Treatment |
2.2.2.End User |
2.2.3.Region |
3.Global Leukocyte Adhesion Deficiency Management Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Leukocyte Adhesion Deficiency Management Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Leukocyte Adhesion Deficiency Management Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Hematopoietic Stem Cell Transplantation |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Recombinant Human Interferon-gamma Treatment |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Prophylactic Immunoglobulin Therapy |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Antimicrobial Therapy |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Prophylactic Therapy |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Fucose Supplementation |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Monoclonal Antibodies |
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
5.8. Coagulation Factors |
5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.8.3. Market Opportunity Analysis |
6.Global Leukocyte Adhesion Deficiency Management Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Hospitals |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Specialty Clinics |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Others |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Leukocyte Adhesion Deficiency Management Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8.North America Leukocyte Adhesion Deficiency Management Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Hematopoietic Stem Cell Transplantation |
8.1.2.Recombinant Human Interferon-gamma Treatment |
8.1.3.Prophylactic Immunoglobulin Therapy |
8.1.4.Antimicrobial Therapy |
8.1.5.Prophylactic Therapy |
8.1.6.Fucose Supplementation |
8.1.7.Monoclonal Antibodies |
8.1.8.Coagulation Factors |
8.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Hospitals |
8.2.2.Specialty Clinics |
8.2.3.Others |
8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9.Europe Leukocyte Adhesion Deficiency Management Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Hematopoietic Stem Cell Transplantation |
9.1.2.Recombinant Human Interferon-gamma Treatment |
9.1.3.Prophylactic Immunoglobulin Therapy |
9.1.4.Antimicrobial Therapy |
9.1.5.Prophylactic Therapy |
9.1.6.Fucose Supplementation |
9.1.7.Monoclonal Antibodies |
9.1.8.Coagulation Factors |
9.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hospitals |
9.2.2.Specialty Clinics |
9.2.3.Others |
9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
10.Asia Pacific (APAC) Leukocyte Adhesion Deficiency Management Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Hematopoietic Stem Cell Transplantation |
10.1.2.Recombinant Human Interferon-gamma Treatment |
10.1.3.Prophylactic Immunoglobulin Therapy |
10.1.4.Antimicrobial Therapy |
10.1.5.Prophylactic Therapy |
10.1.6.Fucose Supplementation |
10.1.7.Monoclonal Antibodies |
10.1.8.Coagulation Factors |
10.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hospitals |
10.2.2.Specialty Clinics |
10.2.3.Others |
10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11.Middle East and Africa (MEA) Leukocyte Adhesion Deficiency Management Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Hematopoietic Stem Cell Transplantation |
11.1.2.Recombinant Human Interferon-gamma Treatment |
11.1.3.Prophylactic Immunoglobulin Therapy |
11.1.4.Antimicrobial Therapy |
11.1.5.Prophylactic Therapy |
11.1.6.Fucose Supplementation |
11.1.7.Monoclonal Antibodies |
11.1.8.Coagulation Factors |
11.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hospitals |
11.2.2.Specialty Clinics |
11.2.3.Others |
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12.Latin America Leukocyte Adhesion Deficiency Management Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Hematopoietic Stem Cell Transplantation |
12.1.2.Recombinant Human Interferon-gamma Treatment |
12.1.3.Prophylactic Immunoglobulin Therapy |
12.1.4.Antimicrobial Therapy |
12.1.5.Prophylactic Therapy |
12.1.6.Fucose Supplementation |
12.1.7.Monoclonal Antibodies |
12.1.8.Coagulation Factors |
12.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hospitals |
12.2.2.Specialty Clinics |
12.2.3.Others |
12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Orpha Labs |
13.2.2.Avalo Therapeutics, Inc. |
13.2.3.Rocket Pharmaceuticals Inc. |
13.2.4.Sigma-Aldrich |
13.2.5.Aspen Neuroscience |
13.2.6.Magenta Therapeutics |
13.2.7.Rubius Therapeutics |
13.2.8.Enochian Biosciences |
13.2.9.Sana Biotechnology |
13.2.10.Vertex Pharmaceuticals |
14. Research Methodology |
15. Appendix and Abbreviations |